Zogenix Reports First Quarter 2013 Financial Results
09 mai 2013 16h01 HE
|
Zogenix
Provides Update on Zohydro ER
Conference Call and Webcast Today, May 9, at 4:30 p.m. ET
SUMAVEL® DosePro® (sumatriptan injection) First Quarter 2013 Highlights
Net product...
Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results
03 mai 2013 07h30 HE
|
Zogenix
SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain,...
Zogenix Reports Positive Top-Line Results From Extended Relday(TM) Phase 1 Clinical Trial
02 mai 2013 07h30 HE
|
Zogenix
SAN DIEGO, May 2, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain,...
Zogenix and Battelle Extend DosePro Co-Marketing Partnership
27 mars 2013 08h00 HE
|
Zogenix
SAN DIEGO and COLUMBUS, Ohio, March 27, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous...
Zogenix Reports Fourth Quarter and Full Year 2012 Financial Results
15 mars 2013 07h30 HE
|
Zogenix
SUMAVEL® DosePro® (sumatriptan injection) Highlights
2012 net product revenue of $35.9 million, up 18% over 2011
Fourth quarter net product revenue of $9.5 million, up 12% over...
Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2012 Financial Results
07 mars 2013 07h30 HE
|
Zogenix
SAN DIEGO, March 7, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix Provides Update on Zohydro(TM) ER Regulatory Review
26 févr. 2013 20h05 HE
|
Zogenix
SAN DIEGO, Feb. 26, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix Announces Preliminary Fourth Quarter 2012 Gross Product Sales
07 janv. 2013 07h30 HE
|
Zogenix
SAN DIEGO, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix Reports Positive Results From Relday(TM) Phase 1 Clinical Trial
03 janv. 2013 07h30 HE
|
Zogenix
SAN DIEGO, Jan. 3, 2013 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain,...
Zogenix Provides Update on FDA Advisory Committee Meeting for Zohydro(TM) ER for Management of Chronic Pain
07 déc. 2012 17h45 HE
|
Zogenix
SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...